Scarica l'app Stockscreener
5.87
2.94%
0.09
Precedente Chiudi:
$5.78
Aprire:
$5.85
Volume 24 ore:
12,532
Relative Volume:
0.22
Capitalizzazione di mercato:
$94.16M
Reddito:
-
Utile/perdita netta:
$-14.88M
Rapporto P/E:
-5.9898
EPS:
-0.98
Flusso di cassa netto:
$-10.29M
1 W Prestazione:
+0.85%
1M Prestazione:
+5.31%
6M Prestazione:
-2.62%
1 anno Prestazione:
-0.34%
Intervallo 1D:
$5.76
$5.985
Intervallo di 1 settimana:
$5.5665
$6.34
Portata 52W:
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
Nome
Coya Therapeutics Inc
Settore
Industria
Telefono
650.739.3939
Indirizzo
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Confronta COYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.87 | 94.16M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.42 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.97 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.41 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.16 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.90 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-04 | Iniziato | D. Boral Capital | Buy |
Coya Therapeutics Inc Borsa (COYA) Ultime notizie
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025 - Business Wire
Trading (COYA) With Integrated Risk Controls - news.stocktradersdaily.com
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from HC Wainwright - Defense World
Coya Therapeutics (COYA) Receives Confirmed Buy Rating from HC W - GuruFocus
Coya Therapeutics (COYA) Receives Confirmed Buy Rating from HC Wainwright | COYA Stock News - GuruFocus
Coya Therapeutics (COYA) Rated Buy by Analyst with $20 Target | COYA Stock News - GuruFocus
Jane Street Group LLC Makes New $74,000 Investment in Coya Therapeutics, Inc. (NASDAQ:COYA) - Defense World
(COYA) Trading Report - news.stocktradersdaily.com
Northern Trust Corp Has $164,000 Stock Position in Coya Therapeutics, Inc. (NASDAQ:COYA) - Defense World
Coya Therapeutics secures patent for IL-2 liquid formulation By Investing.com - Investing.com South Africa
Coya Therapeutics secures patent for IL-2 liquid formulation - Investing.com
Coya Therapeutics (COYA) Secures U.S. Patent for IL-2 Liquid Formulation | COYA Stock News - GuruFocus
Coya's Exclusive Patent Win Strengthens IL-2 Drug Pipeline as Phase 2b ALS Trial Approaches - Stock Titan
(COYA) Investment Report - news.stocktradersdaily.com
Brokers Issue Forecasts for COYA Q1 Earnings - Defense World
Q3 EPS Forecast for Coya Therapeutics Increased by Analyst - Defense World
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating - TipRanks
Coya Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
FY2026 Earnings Forecast for COYA Issued By Chardan Capital - Defense World
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Business Wire
Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Holdings Lifted by Tower Research Capital LLC TRC - Defense World
Coya Therapeutics (COYA): Analyst Maintains Buy Rating and Price - GuruFocus
Critical Survey: Coya Therapeutics (NASDAQ:COYA) vs. BioVie (NASDAQ:BIVI) - Defense World
Coya Therapeutics Reports Q1 2025 Financial Results - TipRanks
Coya (COYA) Reports Lower Q1 Revenue Than Expected | COYA Stock News - GuruFocus
Coya Therapeutics (COYA) Reports Q1 EPS and Cash Position - GuruFocus
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - Stock Titan
Coya Therapeutics (COYA) Projected to Post Quarterly Earnings on Thursday - Defense World
How To Trade (COYA) - news.stocktradersdaily.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Geode Capital Management LLC - Defense World
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Biotech Company Reports Promising Neurological Treatment in Clinical Study - streetwisereports.com
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
Coya Therapeutics Announce Positive Interim Result from - openPR.com
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com
Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com
Coya stock in focus after interim results for dementia drug - Seeking Alpha
Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph
Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com
Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance
AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com
Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com
Coya Therapeutics Inc Azioni (COYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Coya Therapeutics Inc Azioni (COYA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):